Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF) on no Background Anti-fibrotic Therapy
Latest Information Update: 25 Jul 2022
At a glance
- Drugs Nerandomilast (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 23 Oct 2019 Status changed from active, no longer recruiting to completed.
- 15 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 03 Apr 2019 Planned number of patients changed from 18 to 24.